Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia

Table 1 Relationship between clinicopathological characteristics and CCL2 expression in gastric cancer

Clinical characteristic	CCL2 expression level		P value1
	High	Low
Gender			0.091
Male	36	14
Female	9	9
Age (yr)			0.772
< 49.82	16	9
≥ 49.82	29	14
Tumor diameter (cm)			0.595
≤ 5	8	2
5-10	8	5
> 10	29	16
Differentiation grade			0.571
Well	2	2
Moderate	16	10
Poor	27	11
Histopathology			0.387
Tubular	14	6
Poorly	19	11
Signet-ring	7	1
Mucinous	5	5
Lymph node metastasis			0.954
Yes	14	7
No	31	16
AJCC stage2			0.268
I/II	21	14
III/IV	24	9

¹χ² or Fisher exact test;

²AJCC: American Joint Committee on Cancer.

Table 2 Evaluation of all significant factors in the multivariate Cox regression model

	Survival time
	HR (95%CI)	P value
Gender	1.198 (0.531-2.703)	0.664
Male vs female
Tumor volume	1.086 (0.660-1.788)	0.744
> 5 cm vs < 5 cm
Differentiation	0.637 (0.310-1.310)	0.221
Mid + High vs Low
Lymph node	1.109 (0.484-2.541)	0.806
Yes vs No
AJCC stage	3.242 (1.467-7.163)	0.004
I/II vs III/IV
CCL2 expression	2.311 (1.019-5.241)	0.045
High vs Low

AJCC: American Joint Committee on Cancer.